A key event for R&D and innovation
BioFIT is one of Europe’s leading events dedicated to early-stage innovation, technology transfer, licensing and collaborative research in biotechnology and biopharmaceutical sciences. Each year, the event brings together more than one thousand participants, including major pharmaceutical groups, emerging biotechs, academic research institutions, technology transfer offices, and investors specialising in life sciences.
This year, Cellura will attend BioFIT 2025 to present its gentle and scalable bioproduction technology designed for fragile and sensitive cells. The event provides an ideal platform to initiate new scientific collaborations, explore industrial partnerships, and introduce the SoftXS™ bioreactor to organisations seeking reproducible and low-shear 3D culture solutions.
A Strategic Event for Early-Stage Innovation and Technology Transfer
BioFIT occupies a central role in the European innovation landscape. It is recognised for its focus on the earliest stages of the development pipeline, where breakthroughs originating from academic research begin their transition towards industrial application.
The event addresses several major themes that align closely with Cellura’s mission:
1. Technology transfer and academic collaboration
BioFIT is considered the leading marketplace in Europe for connecting universities, research hospitals, and industry. It promotes the valuation of academic discoveries and supports the creation of collaborative research projects and licensing opportunities.
2. Biopharma and translational research
Participants include scientific and clinical groups working on regenerative medicine, stem cells, immune cell engineering, organoid models, complex 3D biology, toxicology and early drug development. These fields correspond directly to the applications for which the SoftXS™ bioreactor has demonstrated strong value.
3. Investment and company growth
The event attracts venture capital firms, corporate investors, and innovation funds seeking promising early-stage technologies. As Cellura continues to expand across Europe and engage with new industrial and clinical partners, BioFIT represents an important moment to meet stakeholders involved in early financing and strategic development.
SoftXS™, a Bladeless 3D Bioreactor Engineered for Fragile Cells
SoftXS™ introduces a unique mixing system inspired by the Earth’s rotational mechanics. Developed from research at CNRS and used in collaboration with experts from AP-HP and INSERM, the technology generates homogeneous chaotic mixing while keeping shear stress extremely low.
Key characteristics
Controlled shear forces significantly lower than those observed in stirred-tank or fixed-bed systems.
Homogeneous mixing without dead zones, allowing uniform distribution of nutrients and oxygen.
Linear scalability, validated from 125 mL to 500 mL and up to 200 L in laboratory conditions.
Compatibility with a wide portfolio of sensitive cell types, including pluripotent stem cells, organoids, immune cells, and adherent cells grown on microcarriers.
Validated results
iPSC cultures expanded one hundredfold in seven days while preserving more than 99 percent stemness.
Natural killer cells expanded tenfold in seven days under single-cell culture conditions.
Organoids formed in stable, homogeneous suspension with maintained viability.
Microcarriers resuspended gently at only 30 to 60 rpm in low-shear conditions.
These results demonstrate the capacity of SoftXS™ to support applications ranging from academic research to industrial bioproduction.
Validated in collaboration with Prof. Annelise Bennaceur (INSERM / CITHERA) and Prof. Ali Turhan (Université Paris-Saclay), our results demonstrated:
100-fold iPSC amplification in 7 days with >99% preserved stemness,
>90% viability for NK cells cultured in 3D,
Full compatibility with Corning® microcarriers, enabling suspension at very low speeds (30 rpm) and shear stress up to 50× lower than in stirred-tank or fixed-bed systems,
Consistent scalability from 1 L to 200 L with identical culture parameters.
These data are detailed in our technical report:
“Microcarriers Suspension Characterization in a Rotating 3D Bioreactor”, Roumezi B. & Detournay O., 2025.
Why BioFIT Matters for Cellura
Cellura’s participation in BioFIT 2025 aims to promote scientific, operational, and industrial collaborations. Several collaboration opportunities will be explored during the event.
Research and development partnerships
Discussions will focus on integrating SoftXS™ into workflows involving stem cells, immune cells, organoids, microcarriers, and advanced model systems. The goal is to support researchers seeking greater reproducibility, lower shear stress, and more controlled 3D culture environments.
Pre-GMP development and scale-up
SoftXS™ enables laboratories and early-stage companies to transition from small-volume research to scalable processes without redesign. The reproducibility of operating parameters supports faster optimisation and reduces integration complexity.
Licensing and technology evaluation
BioFIT is a key environment for presenting technologies to transfer offices and early adopters. Cellura will explore evaluation agreements and collaborations aimed at validating 3D culture processes on the SoftXS™ platform.
Industrial bioproduction
For CDMOs and biotechnology companies, discussions will include process robustness, multi-client adaptability, automation perspectives, and compatibility with future GMP requirements.
Investment and expansion
The event offers opportunities to engage investors supporting the development of next-generation bioproduction platforms. Cellura will present its scale-up strategy and development roadmap.
Towards a New Standard in Bioproduction for Sensitive Cells
The challenges associated with the culture and industrial scale-up of fragile cells are central to many of the discussions taking place at BioFIT, particularly those related to reproducibility, ethical research practices, reduction of animal testing, and the need for new biomanufacturing infrastructures.
Cellura’s approach aims to address these issues through a gentle, controllable, and scalable technology that improves biological relevance while facilitating operational implementation.
Meet Cellura at BioFIT 2025
The Cellura team will be available during the event to discuss scientific needs, technical constraints, collaboration opportunities, and the integration of SoftXS™ into existing workflows.
For further information or to arrange a meeting:
Email: contact@cellura.io
